TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03989518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fear acquisition
Description: Day 1. Participants are exposed to two different visual stimuli. One of these stimuli is paired with a mild electric shock (i.e. conditioned stimuli).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fear acquisition
Description: Day 1. Participants are exposed to two different visual stimuli. One of these stimuli is paired with a mild electric shock (i.e. conditioned stimuli).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imaginal extinction
Description: Day 2 (24 hours after Day 1). Participants are exposed to mental imagery of the stimuli used during fear conditioning. Imagery is prompted through different verbal instructions presented in a pseudo-randomized order. No shocks are delivered. Prior to imaginal extinction, participants receive task specific training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imaginal extinction
Description: Day 2 (24 hours after Day 1). Participants are exposed to mental imagery of the stimuli used during fear conditioning. Imagery is prompted through different verbal instructions presented in a pseudo-randomized order. No shocks are delivered. Prior to imaginal extinction, participants receive task specific training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinstatement
Description: Day 3 (48 h after day1). Participants are exposed to the same stimuli used during fear conditioning (day 1) and imaginal extinction (day 2). Two unsignaled shocks are delivered at the beginning of the experiment, prior to the presentation of the first visual stimulus. No further shocks are delivered. This procedure allows the study of long term effects of imaginal extinction.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinstatement
Description: Day 3 (48 h after day1). Participants are exposed to the same stimuli used during fear conditioning (day 1) and imaginal extinction (day 2). Two unsignaled shocks are delivered at the beginning of the experiment, prior to the presentation of the first visual stimulus. No further shocks are delivered. This procedure allows the study of long term effects of imaginal extinction.
Study: NCT03983603

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soft chews containing 0.5g plant stanols (delivered as plant stanol esters)
Description: Soft chews containing 0.5g plant stanols delivered as plant stanol esters

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo soft chew
Description: Soft chew that does not contain plant stanols
Study: NCT02729285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: On operation day, the patients were randomly assigned to receive intramuscular Ketorolac 60-mg 30 min before scleral buckle surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: On operation day, the patients were randomly assigned to receive placebo 30 min before scleral buckle surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: scleral buckle
Description: Surgical procedure of scleral buckle under retrobulbar block anesthesia

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: scleral buckle
Description: Surgical procedure of scleral buckle under retrobulbar block anesthesia
Study: NCT00950326

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: In intervention group B1, patients with osteoarthritis of the hip or knee will receive specific physiotherapy of the affected hip or knee joint three times a week, but without any disease-specific hydrotherapy. Because of the holistic approach of the clinic, however, these patients will still receive hydrotherapy at sites other than the affected joint, for example, alternate cold and warm affusions of the back or an ascending lumbar affusion.
Study: NCT01423500

Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine, OKT3, Treosulfan, Thiotepa
Description: patients with a MMD (haploidentical or cord blood) receive Fludarabine 30mg/m²/d on day -9 to -5, ATG fresenius 20mg/kg/d on day -3,-2,-1, Treosulfan 14g/m²/d on day -7 to -5 and Thiotepa 2x5mg/kg/d on day -4

Intervention type: DRUG
Group type: OTHER
Intervention: VP16, ATG
Description: patients with MMD-transplantation (8/10)receive VP16 60mg/kg/d on day -4, ATG from day -3 to day-1 20mg/kg/d

Intervention type: RADIATION
Group type: OTHER
Intervention: TBI
Description: patients with a MMD-transplantation (8/10) receive 12 Gy in 6 fractions
Study: NCT05322798

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-frequency SCS
Description: Continous high-frequency stimulation (frequency - 1kHz, pulse width - 30 µs).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low-frequency SCS
Description: Continuous conventional stimulation (frequency - 30-60 Hz, pulse width - 250-500 µs).
Study: NCT03138369

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vestibular nerve stimulator
Description: Battery powered headset that can be recharged when not being used.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham vestibular stimulation
Description: Identical in external appearance to the vestibular nerve stimulation device, this device is also powered by a battery and needs to be periodically recharge when not being used. However it discharges into an internal resistor and does not stimulate the vestibular nerve.
Study: NCT00950326

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Affusion
Description: Patients will receive a specific hydrotherapeutic procedure in the form of alternate cold and warm thigh affusions ( pouring on water) which will consist of repeated cold and warm water stimulation of the knee and hip region (daily). Physiotherapy of other regions, such as the back, is permitted but there will be no specific physiotherapy of the hip or knee joint.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Affusion/ Physiotherapy
Description: Patients with active osteoarthritis of the hip or knee will receive specific, joint-related hydrotherapy in the form of a (daily) alternate cold and warm thigh affusions as well as joint-specific physiotherapy (three times a week).
Study: NCT00797251

Intervention type: PROCEDURE
Intervention: Anatomical right posterior sectionectomy of the liver by IOUS-guided finger compression.
Description: The technique consists in IOUS-guided finger compression of the right posterior portal pedicle at the level closest to the tumor but oncologically suitable. This method allows us to anatomically mark the area of resection with nor hilar plate nor IOUS-guided puncture of vessels, which are up to date the only two techniques available to perform anatomical right posterior sectionectomy - namely the removal of segment 6 and 7.
Study: NCT00690560

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan
Study: NCT04238273

Intervention type: DIAGNOSTIC_TEST
Intervention: Functional Echocardiography
Description: Imaging studies to assess Hemodynamics of both groups on and off non invasive ventilation
Study: NCT05672758

Intervention type: BEHAVIORAL
Intervention: Sprint training
Description: One-year cycle including specific sprint-oriented athletic training

Intervention type: BEHAVIORAL
Intervention: Endurance training
Description: One-year cycle including specific endurance-oriented athletic training

Intervention type: BEHAVIORAL
Intervention: Recreational Training
Description: One year of nonspecific recreational training
Study: NCT04716764

Intervention type: OTHER
Intervention: 3-Day Food Intake Record
Description: Collecting clinical and socio-demographic information, nutritional status, food consumption (dietary intake of advanced glycation end products, dietary total antioxidant capacity, dietary inflammatory index), anthropometric measurements (body weight, height, body composition, handgrip strength, upper-middle arm circumference, waist circumference, hip circumference, triceps skinfold thickness), quality of life, biochemical biomarkers (serum carboxymethyl lysine, advanced glycation end products receptor, the soluble receptor of advanced glycation end products, TNF-α, IL-1β, IL-6, malondialdehyde, 2,4-dinitrophenyl hydrazine, 8-hydroxy-2'-deoxyguanosine, total antioxidant capacity)
Study: NCT02379104

Intervention type: DEVICE
Intervention: ROTEM sigma
Description: Group Healthy Volunteers: a blood sample is tested with ROTEM sigma Group Patients with expected coagulopathy: a blood sample is tested with ROTEM sigma and ROTEM delta in parallel

Intervention type: DEVICE
Intervention: ROTEM sigma
Description: Group Healthy Volunteers: a blood sample is tested with ROTEM sigma Group Patients with expected coagulopathy: a blood sample is tested with ROTEM sigma and ROTEM delta in parallel
Study: NCT02951767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg will be given by IV infusion on Day 1 of 21-day cycles until disease progression per RECIST v1.1 criteria or unmanageable toxicity.
Study: NCT01237587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Duloxetine
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT00513604

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given subcutaneously every 8 hours for up to 15 doses, day 0, 720,000 IU/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given subcutaneously every 8 hours for up to 15 doses, day 0, 720,000 IU/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given subcutaneously every 8 hours for up to 15 doses, day 0, 720,000 IU/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given subcutaneously every 8 hours for up to 15 doses, day 0, 720,000 IU/kg
Study: NCT00513604

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given subcutaneously every 8 hours for up to 15 doses, day 0, 720,000 IU/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes
Description: Given as infusion, up to 3 x 10\^11 lymphocytes (minimum of 1 x 10\^9), day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes
Description: Given as infusion, up to 3 x 10\^11 lymphocytes (minimum of 1 x 10\^9), day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes
Description: Given as infusion, up to 3 x 10\^11 lymphocytes (minimum of 1 x 10\^9), day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes
Description: Given as infusion, up to 3 x 10\^11 lymphocytes (minimum of 1 x 10\^9), day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes
Description: Given as infusion, up to 3 x 10\^11 lymphocytes (minimum of 1 x 10\^9), day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given intravenously 60 mg/kg/day, day -7 to -6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given intravenously 60 mg/kg/day, day -7 to -6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given intravenously 60 mg/kg/day, day -7 to -6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given intravenously 60 mg/kg/day, day -7 to -6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given intravenously 60 mg/kg/day, day -7 to -6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: Given intravenously 25 mg/m\^2/day over 15-30 minutes, day -5 to -1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: Given intravenously 25 mg/m\^2/day over 15-30 minutes, day -5 to -1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: Given intravenously 25 mg/m\^2/day over 15-30 minutes, day -5 to -1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: Given intravenously 25 mg/m\^2/day over 15-30 minutes, day -5 to -1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: Given intravenously 25 mg/m\^2/day over 15-30 minutes, day -5 to -1

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: 600 cGy
Study: NCT03231501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epitinib succinate
Description: This is a single-arm open label study. A subject would take 160 mg of the study medication (epitinib succinate) every day on a 28-day cycle, until he or she reaches disease progression or intolerability.
Study: NCT01739491

Intervention type: DRUG
Intervention: No intervention
Description: This is an obeservational study. Bendamustine hydrochloride will be administered (as per product insert) through intravenous infusion over 30-60 minutes at 100 mg/meter square body surface area on days 1 and 2 of a 28-day cycle.
Study: NCT04085965

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Boys and Girls Club summer day camp
Description: Daily camp activities included sports, games, obstacle courses, swimming and boating, summer learning and arts and crafts. Lunch was served daily via the USDA's Summer Food Service Program.
Study: NCT03063801

Intervention type: OTHER
Intervention: Data extraction in medical files
Description: Data extraction from medical files, countraverified by the bloodbank database for accuracy.
Study: NCT03334136

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25-Hydroxyvitamin D
Description: Capsules containing 20 000 IU 25-hydroxyvitamin D given orally: five capsules the first day and thereafter one capsule every week for 4 months (average daily dose approximately 3.000 IU)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Five capsules the first day and thereafter one capsule every week for 4 months.
Study: NCT01870232

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US guided block
Description: Greater palatine nerve or inferior alveolar nerve blocks will be performed under US guidance
Study: NCT02721173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% gel plus clindamycin 1% gel
Description: Medications will be advised to apply once daily in the evening after facial cleansing. Clindamycin will be applied first and tazarotene will be applied 5-10 minutes later.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adapalene 0.1% gel plus clindamycin 1% gel
Description: Medications will be advised to apply once daily in the evening after facial cleansing. Clindamycin will be applied first and adapalene will be applied 5-10 minutes later.
Study: NCT02822586

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TSEB Therapy
Description: TSEB is a type of radiation treatment in which the skin over the whole body is treated with electron radiation beams. All participants will receive the same standard TSEB dose and treatment schedule. During TSEB, patients are treated in a standing position on a rotating platform.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TSEB Therapy
Description: TSEB is a type of radiation treatment in which the skin over the whole body is treated with electron radiation beams. All participants will receive the same standard TSEB dose and treatment schedule. During TSEB, patients are treated in a standing position on a rotating platform.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: An antibody-drug conjugate (ADC) that targets CD30. A standard dose of brentuximab vedotin will be administered to all patients by intravenous infusion 3 weeks prior to initiation of TSEB and then every 3 weeks for 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: An antibody-drug conjugate (ADC) that targets CD30. A standard dose of brentuximab vedotin will be administered to all patients by intravenous infusion 3 weeks prior to initiation of TSEB and then every 3 weeks for 3 cycles.
Study: NCT03241303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: Glucobay tablets on experimental day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablets on experimental day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin (9-39)
Description: Infusion of GLP-1 receptor antagonist as a study tool to block GLP-1 activity on experimental day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Saline
Description: 9 mg/ml placebo saline infusion on experimental day.
Study: NCT01981772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4% lidocaine with 1:100,000 epinephrine
Description: see arm/group description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% buffered lidocaine with 1:100,000 epinephrine
Description: see arm/group description
Study: NCT02125747

Intervention type: OTHER
Group type: OTHER
Intervention: No Respiratory Therapy
Description: Patients received conventional treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory Therapy
Description: Respiratory Therapy consists of postural drainage, positive expiratory pressure (PEP) and vibropercussion (it is a postural drainage method, which uses chest clapping with a flexible wrist and cupped hands or a mechanical vibrator to loosen and mobilize retained secretions that can then be expectorated or drained). Postural drainage is an airways clearance technique in which patient's body is positioned so that the trachea is inclined downward and below the affected chest area.~The PEP consists of expiratory cycles through a system generating a positive pressure of 10-20 cc (cubic centimeter) water. Vibropercussion is applied by the use of a mechanical system following rib movement during expiration to enhance clearance of secretions.~Intervention group received 30-minute-sessions twice a day, 7 days per week, during hospitalization period.
Study: NCT01011387

Intervention type: PROCEDURE
Group type: OTHER
Intervention: NPWT System
Description: Dressing change 3 times per week

Intervention type: DEVICE
Group type: OTHER
Intervention: NPWT system
Description: 3 dressing changes/week for maximum 4 weeks.
Study: NCT00950950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study: NCT02639598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flunarizine
Description: as in arm descriptions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Description: as in arm descriptions
Study: NCT05380778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep anesthesia
Description: Drug: High dose propofol, fentanyl and sevoflurane Deep Anesthesia~Other Names:~BIS lower than or equal to 45

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shallow anesthesia
Description: Drug: Low dose propofol, fentanyl and sevoflurane Shallow Anesthesia~Other Names:~BIS above 45
Study: NCT01520220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2784544
Description: LY2784544 will be taken by mouth per a specified schedule. Each cycle is 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2784544
Description: LY2784544 will be taken by mouth per a specified schedule. Each cycle is 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2784544
Description: LY2784544 will be taken by mouth per a specified schedule. Each cycle is 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2784544
Description: LY2784544 will be taken by mouth per a specified schedule. Each cycle is 28 days.
Study: NCT02059785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pinocembrin for Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pinocembrin for Injection
Study: NCT02516475

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: zinc sulfate
Description: 1 zinc sulfate capsule for 15 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: corn starch
Description: 1 corn starch capsule for 15 weeks
Study: NCT01178385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Description: Therapists will work with families for 16 weekly sessions implementing the Behavioral Interventions for Anxiety in Children with Autism (BIACA) CBT program, which is a modified version of a family CBT treatment manual for typically developing children with anxiety disorders. The BIACA intervention program is flexible in nature and employs a modular format. Despite the added flexibility of the modular format, a minimum of three sessions are spent on basic coping skills and eight are spent on in vivo exposure to ensure an adequate and comparable dose of the core elements of CBT for anxiety across cases.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Participants randomized to this arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
Study: NCT02757391

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adoptive Immunotherapy
Description: Undergo CD8 +T cell therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV